Cytomegalovirus reactivation following chemoradiation for invasive cervical carcinoma  by Schlumbrecht, Matthew et al.
Gynecologic Oncology Reports 1 (2011) 22–23
Contents lists available at SciVerse ScienceDirect
Gynecologic Oncology Reports
j ourna l homepage: www.e lsev ie r .com/ locate /gynorCase Report
Cytomegalovirus reactivation following chemoradiation for invasive
cervical carcinoma
Matthew Schlumbrecht a,⁎, Kevin Grimes b, Jubilee Brown a
a Division of Gynecologic Oncology and Reproductive Medicine, Department of Surgery, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA
b Division of Infectious Disease, Department of Internal Medicine, Weill Cornell Medical College, The Methodist Hospital, Houston, Texas, USAa r t i c l e i n f oArticle history:
Received 11 July 2011
Accepted 25 August 2011
Available online 31 August 2011
Keywords:
Cytomegalovirus
Fever of unknown origin
ChemotherapyIntroduction
Cytomegalovirus (CMV) reactivation is an uncommon complication
of chemotherapeutic treatments in patients with solid malignancies.
Here we present the case of a patient with locally advanced cervical
adenocarcinoma who experienced reactivation of a latent CMV in-
fection after starting concomitant chemoradiation for her disease.
Case
A 57-year-old female with no signiﬁcant medical history presented
to her gynecologist with post-menopausal bleeding. Her endometrial
biopsy noted FIGO Grade 1 endometrioid adenocarcinoma, and the
patient was taken to the operating room for total laparoscopic hys-
terectomy. Frozen section intraoperatively, however, was signiﬁcant for
endocervical adenocarcinoma. During the same anesthesia, the patient
underwent radical parametrectomy, bilateral salpingo-oophorectomy,
and pelvic lymph node dissection. Final pathology revealed metastatic
cervical carcinoma in several lymph nodes, and the patient was disposi-
tioned to adjuvant chemoradiation with weekly cisplatin.
At the patient's appointment following 1 week of radiation, and
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Open access under CC BY-NC-ND license.low-grade fevers and extreme fatigue. Shewasnoted to have leukopenia
and a temperature of 100.6 °F. The remainder of her lab work, including
electrolytes and liver function tests, was normal. Given her array of
symptoms, she was admitted to the hospital for evaluation. During the
ﬁrst 24 h of her hospitalization, she had fevers that reached 104 °F. She
was empirically started on intravenous piperacillin-tazobactam. Initial
chest X-ray and blood cultures were negative; a urine culture subse-
quently grew N105 pan-sensitive Escherichia coli. The patient's white
blood cell count nadired at 2500/UL on hospital day 3; her absolute neu-
trophil count never fell below 1800/UL.
Despite appropriate antibiotic coverage, the patient continued to
have fevers greater than 102 °F. Antibiotic coverage was expanded
to include metronidazole and vancomycin. Subcutaneous ﬁlgrastim
was started for bone marrow support. A thorough work-up with as-
sessment of multiple parameters was undertaken (Table 1).
Given the patient's persistent febrile neutropenia, Infectious Disease
was consulted. Repeat liver function tests revealed mildly elevated
transaminases (ALT 174, AST 199), and a hepatitis evaluation begun
(Table 1). As part of this work-up, the patient's CMV DNA viral load
was measured, and found to be 7279 copies/mL. Both her CMV IgM
and IgG were positive. She was given a diagnosis of CMV reactivation
with hepatitis resulting from immunosuppression induced by chemora-
diation, and was initiated on oral valgancyclovir. The patient was ul-
timately able to continue her chemoradiation while on antiviral
medication, and at the conclusion of therapy had normal hematologic
parameters with signiﬁcantly less fatigue.
Discussion
Infection with CMV is common. In fact, it was recently reported that
the seroprevalence of CMV in the United States is 50.4% (Bate et al.,
2010). CMV is acquired through contact with infected body ﬂuids, and
the majority of infections are subclinical and asymptomatic (Bate
et al., 2010).
Several prospective studies have evaluated CMV reactivation in
populations of patients with both solid and hematologic malignancies.
Capria et al. (2010) reported on a group of patients with acute myeloid
leukemia receivingmulti-agent chemotherapy. Of those patients with a
positive CMV IgG and negative CMV IgM prior to starting chemo-
therapy, 35% developed CMV reactivation. (Cheung et al., 2007) fol-
lowed a group of ten patients with lymphoid malignancies treated
with the monoclonal antibody alemtuzumab (anti-CD52), and noted
that 100% experienced CMV reactivation at a median of 19 days after
Table 1
Laboratory and imaging studies performed as part of patient's work-up.
Study Result
Laboratory
Urine culture N105 Escherichia coli, pan-sensitive
Stool cultures/ova and parasites Negative
Blood cultures Negative
Clostridium difﬁcile toxin Negative
Fecal leukocyte Negative
HIV 1/2 IgG Nonreactive
Urine eosinophils Negative
Anti-nuclear antibody (ANA) Negative
Hepatitis A IgM Nonreactive
Hepatitis B surface antigen Nonreactive
Hepatitis B core antibody (IgM) Nonreactive
Hepatitis C IgG Nonreactive
Lyme disease antibody Negative
CMV IgM Positive
CMV IgG Positive
CMV DNA viral load 7279 copies/mL
Erythrocyte sedimentation rate (ESR) 82 mm/HR
Imaging
Chest X-ray Negative
CT abdomen/pelvis Negative
Right upper quadrant ultrasound Negative
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tients: one experienced hemorrhagic pneumonitis and another devel-
oped hepatitis.
Though CMV reactivation has been less commonly reported in
patients with solid tumors, a case series by Kuo et al. in patients
with lung, rectal, and head and neck cancers noted that rates of
CMV reactivation are actually similar to those in hematologic malig-
nancies (Kuo et al., 2008). The authors followed ﬁfteen participants
and performed serial testing for CMV DNA. Of the 15 patients, 14 expe-
rienced increases in their CMV viral loads. Symptomatologywas direct-
ly correlatedwith CMVviral loads; thosewhowere asymptomatic had a
median viral load of 1540 copies/mL while death was associated with
signiﬁcantly higher viral loads (median 26,790 copies/mL).
Our patient's presentation was unique in that she received only
several days of radiation treatment and one dose of cisplatin. She
had no prior knowledge of her CMV infection. Consistent with the
ﬁndings by Kuo et al., our patient, though febrile, had only a moder-
ate viremia and demonstrated minimal end-organ (hepatic) dys-
function. Similarly, she had normalization of her transaminases
after initiating valgancyclovir, a result which was also observed in
the patient in Cheung's report who developed CMV hepatitis
(Cheung et al., 2007).While CMVwas certainly in the differential diagnosis for viral infec-
tion in this patient, other viruses are also commonly reactivated in
patients who become immunosuppressed from chemotherapy and
should be considered in this clinical setting. Hepatitis B virus (HBV),
human herpesvirus-6 (HHV-6), and Epstein–Barr virus (EBV) may all
reactivate in this population. Amongpatientswith hematogenousmalig-
nancies, HBV reactivation is not infrequently encountered, particularly
when combination steroids and rituximab are used (Kusumoto et al.,
2011). In addition, pre-chemotherapy HBV DNA viral loads N106 cop-
ies/mL have been associated with a higher incidence of symptomatic in-
fection after exposure to cytotoxic agents inwomenwith invasive breast
carcinoma (Zhong et al., 2004). Rates of reactivation for HHV-6 and EBV
have been shown to be as high as 52.3% and 21.5%, respectively, in pa-
tients with T-cell leukemia, though in general these pathogens do not
cause long-term sequelae (Ogata et al., 2011).
Screening for latent CMV infection in patients with gynecologic
malignancies is not routine, and there are no prior cases reported
of CMV reactivation in the gynecologic oncology literature. However,
a fever of unknown origin that persists despite appropriate antibiotic
coverage should prompt amore thorough evaluation for pathogens, in-
cluding viruses, whichmay have been reactivated as a result of cytotoxic
interventions for the primary malignancy.
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